The relationship between risk of hypoglycemia and use of cibenzoline and disopyramide

European Journal of Clinical Pharmacology

Volumn 56, Issue 4, 2000, Pages 335-342

  Takada, M ^a   Fujita, S ^a   Katayama, Y ^a   Harano, Y ^a   Shibakawa, M ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

ATP sensitive K+ channel; Cibenzoline; Hypoglycemia

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CIBENZOLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; INSULIN; SULFONYLUREA DERIVATIVE; THYROID HORMONE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0033925968     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000136     Document Type: Article

References (38)

1. 1. Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, Begaud B (1997) Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/ non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 44: 513-518
2. 2. Seltzer HS (1989) Drug-induced hypoglycemia. A review of 1418 cases. Endocrinol Metab Clin North Am 18: 163-183
3. 3. Croxson MS, Shaw DW, Henley PG, Gabriel HD (1987) Disopyramide-induced hypoglycaemia and increased serum insulin. N Z Med J 100: 407-408
4. 4. Goldberg IJ, Brown LK, Rayfield EJ (1980) Disopyramide (Norpace)-induced hypoglycemia. Am J Med 69: 463-466
5. 5. Gachot BA, Bezier M, Cherrier JF, Daubeze J (1988) Cibenzoline and hypoglycaemia. Lancet 2: 280
6. 6. Jeandel C, Preiss MA, Pierson H, Penin F, Cuny G, Bannwarth B, Netter P (1988) Hypoglycaemia induced by cibenzoline. Lancet 1: 1232-1233
7. 7. Hilleman DE, Mohiuddin SM, Ahmed IS, Dahl JM (1987) Cibenzoline-induced hypoglycemia. Drug Intell Clin Pharm 21: 38-40
8. + channels and insulinotrophic action by the antiarrhythmic agent, cibenzoline. Br J Pharmacol 117: 1749-1755
9. 9. Kakei M, Nakazaka M, Kamisaki T, Nagayama I, Fukamachi Y, Tanaka H (1993) Inhibition of the ATP-sensitive potassium channel by class I antiarrhythmic agent, cibenzoline, in rat pancreatic beta-cells. Br J Pharmacol 109: 1226-1231
10. + channels and enhances insulin release. Am J Physiol 265: C337-C342
11. 11. Bertrand G, Gross R, Petit P, Loubatieres-Mariani MM, Ribes G (1992) Evidence for a direct stimulatory effect of cibenzoline on insulin secretion in rats. Eur J Pharmacol 214: 159-163
12. 12. Wu B, Sato T, Kiyosue T, Arita M (1992) Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs. Cardiovasc Res 26: 1095-1101
13. 13. Horie M, Hayashi S, Yuzuki Y, Sasayama S (1992) Comparative studies of ATP sensitive potassium channels in heart and pancreatic β cells using Vaughan-Williams class Ia antiarrhythmics. Cardiovasc Res 26: 1087-1094
14. 14. Shaw LM, Doherty JU, Waxman HL, Josephson ME (1987) The pharmacokinetic and pharmacodynamic effects of varying the fraction of disopyramide. Angiology 38: 192-197
15. 15. Siddoway LA, Woosley RL (1986) Clinical pharmacokinetics of disopyramide. Clin Pharmacokinet 11: 214-222
16. 16. Echizen H, Ishikawa S, Koike K, Ishizaki T (1995) Nomogram for estimating plasma unbound disopyramide concentration in patients with varying plasma α 1-acid glycoprotein concentrations. Ther Drug Monit 17: 145-152
17. 17. Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C (1989) Disopyramide-induced hypoglycemia: case report and review of the literature. Fundam Clin Pharmacol 3: 527-535
18. 18. Strathman I, Schubert EN, Cohen A, Nitzberg DM (1983) Hypoglycemia in patients receiving disopyramide phosphate. Drug Intell Clin Pharm 17: 635-638
19. 19. Brazzell RK, Rees MM, Khoo KC, Szuna AJ, Sandor D, Hannigan J (1984) Age and cibenzoline disposition. Clin Pharmacol Ther 36: 613-619
20. 20. Bonde J, Pedersen LE, Bodtker S, Angelo HR, Svendsen TL, Kampmann JP (1985) The influence of age and smoking on the elimination of disopyramide. Br J Clin Pharmacol 20: 453-458
21. 21. Wu SN, Nakajima T, Yamashita T, Hamada E, Hazama H, Iwasawa K, Omata M, Kurachi Y (1994) Molecular mechanism of cibenzoline-induced anticholinergic action in single atrial myocytes: comparison with effect of disopyramide. J Cardiovasc Pharmacol 23: 618-623
22. 22. Massarella JW, Khoo KC, Aogaichi K, Di Persio D, Smith M, Kluger J, Chow MS (1988) Effect of renal impairment on the pharmacokinetics of cibenzoline. Clin Pharmacol Ther 43: 317-323
23. 23. Francois B, Mallein R, Rondelet J, Lussignol M (1983) Pharmacokinetics of disopyramide in patients with chronic renal failure. Eur J Drug Metab Pharmacokinet 8: 85-92
24. 24. McCrimmon RJ, Frier BM (1994) Hypoglycaemia, the most feared complication of insulin therapy. Diabete Metab 20: 503-512
25. 25. Shorr RI, Ray WA, Daugherty JR, Griffin MR (1996) Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 44: 751-755
26. 26. Harrower AD (1994) Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications 8: 201-203
27. 27. Emilien G, Maloteaux JM, Ponchon M (1999) Pharmacological management of diabetes: recent progress and future perspective in daily drug treatment. Pharmacol Ther 81: 37-51
28. 28. Kumar S, Prange A, Schulze J, Lettis S, Barnett AH (1998) Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients. Diabet Med 15: 772-779
29. 29. Scheen AJ, Lefebvre PJ (1998) Oral antidiabetic agents. A guide to selection. Drugs 55: 225-236
30. 30. Foot EA, Eastmond R (1997) Good metabolic and safety profile of troglitazone alone and following alcohol in NIDDM subjects. Diabetes Res Clin Pract 38: 41-51
31. 31. Bressler R, Johnson DG (1996) Oral antidiabetic drug use in the elderly. Drugs Aging 9: 418-437
32. 32. Chan JC, Cockram CS, Critchley JA (1996) Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 15: 135-157
33. 33. Berne C, Pollare T, Lithell H (1991) Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 14[suppl 4]: 39-47
34. 34. Paolisso G, Gambardella A, Uerza M, D'Amore A, Sgambato S, Varricchio M (1992) ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 6: 175-179
35. 35. Herings RM, de Boer A, Stricker BH, Leufkens HG, Porsius A (1995) Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 345: 1195-1198
36. 36. Clausen N, Lins PE, Adamson U, Hamberger B, Efendic S (1986) Counterregulation of insulin-induced hypoglycaemia in primary hypothyroidism. Acta Endocrinol 111: 516-521
37. 37. Hermansen K, Johannsen LG, Rasmussen OB (1985) Hypoglycaemic coma in severe primary hypothyroidism. Acta Med Scand 218: 345-346
38. 38. Takada M, Nagai S, Shibakawa M, Satoh T, Suyama K, Kyotani S, Kanazawa A, Suzaki M, Komatsu R, Nishioeda Y, Tsushima M, Matsuyama T, Harano Y (1997) Effect of cibenzoline treatment on glucose metabolism in patients with tachyarrhythmia (in Japanese). Ther Res 18: 403-410